5 completed, 1 no longer available, 1 recruiting, 1 unknown. 2 Phase 1, 2 Phase 2, 2 Phase 4, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 2 |
| Phase 2 | 2 | Completed 1, Recruiting 1 |
| Phase 4 | 2 | Completed 1, Unknown 1 |
| Phase 3 | 1 | Completed 1 |
Follow Signifor: new trials by email Literature Review of Signifor trials Research Report on Signifor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pasireotide as Maintenance Treatment in Synovial Sarcoma and Desmoplastic Small Round Cell Tumor Signifor - Desmoplastic Small Round Cell Tumor, Synovial Sarcoma | Phase 2 | Recruiting | University Hospital Heidelberg | 28 | 2024-12-19 | 2025-01-13 |
| Pasireotide in the Treatment of Hypoglycemia Following Gastric Bypass Surgery Pasireotide 0.3 MG/ML, Meal tolerance test (MTT) - Hypoglycemia, Reactive | Phase 4 | Unknown | Zealand University Hospital | 5 | 2018-06-01 | 2018-07-05 |
| Treatment Plan for an Individual Patient With Pasireotide for Hyperinsulinemic Hypoglycemia Pasireotide - Hyperinsulinemic Hypoglycemia, Post Gastrointestinal Tract Surgery Hypoglycaemia | Phase 1 | Completed | University of Colorado, Denver | 1 | 2017-03-22 | 2021-09-29 |
| Treatment of Hypoglycemia Following Gastric Bypass Surgery Glucobay (acarbose), Januvia (sitagliptin), Verapamil HEXAL (verapamil) - Hypoglycemia, Obesity | Phase 4 | Completed | Zealand University Hospital | 11 | 2015-10-01 | 2018-03-07 |
| Long Term Safety and Efficacy of Pasireotide s.c. in Patients With Cushing's Disease Pasireotide - Cushings Disease | Completed | RECORDATI GROUP | 152 | 2013-03-28 | 2024-10-15 | |
| Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases Pasireotide, Sir-sphere Radioembolization, Everolimus - Neuroendocrine Tumors | Phase 1 | Completed | Emory University | 13 | 2011-12-01 | 2018-10-18 |
| Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas Pasireotide, cabergoline - Non-functioning Pituitary Adenomas, Prolactinomas | Phase 2 / Phase 3 | Completed | Universidade Federal do Rio de Janeiro | 21 | 2010-03-01 | 2016-08-22 |
| Compassionate Use of SOM230 for Hyperinsulinemic/Hypoglycemia Pasireotide - Congenital Hyperinsulinism | No longer available | Montefiore Medical Center | 2022-07-29 |
Hypoglycemia (3) · Congenital Hyperinsulinism (2) · Hyperinsulinism (2) · Adrenocortical Hyperfunction (1) · Desmoplastic Small Round Cell Tumor (1) · Liver Neoplasms (1) · Neuroendocrine Tumors (1) · Obesity (1) · Pituitary ACTH Hypersecretion (1) · Prolactinoma (1) · Sarcoma, Synovial (1)
Zealand University Hospital (2) · Emory University (1) · Montefiore Medical Center (1) · RECORDATI GROUP (1) · Universidade Federal do Rio de Janeiro (1) · University Hospital Heidelberg (1) · University of Colorado, Denver (1)
United States (4) · Germany (2) · Brazil (1) · Canada (1) · Colombia (1) · Denmark (1) · France (1) · Israel (1) · Italy (1) · Lebanon (1) · Netherlands (1) · Romania (1) · United Kingdom (1)
Bassel El-Rayes, MD (1) · Caroline C Gormsen, M.D. (1) · Helen Lawler, MD (1) · Mike McDermott, MD (1) · Richard F. Schlenk, Professor (1) · Vafa Tabatabaie (1)